Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study evaluated the Penn State Worry Questionnaire (PSWQ) as a tool for measuring worry and anxiety levels among individuals entering treatment for substance use disorders (SUDs). The sample included 75,047 individuals admitted to SUD treatment centers, with assessments conducted weekly. Individuals entering SUD treatment exhibited higher baseline levels of worry; however, worry levels declined over the course of treatment. The PSWQ demonstrated good internal consistency, high test-retest reliability, and good discriminant validity when correlated with measures of depression and stress. The factor structure analysis confirmed that the PSWQ measures the same underlying construct of worry in the SUD treatment population, with a single-factor model showing satisfactory fit. This extends the reach of the PSWQ to the SUD treatment population by reaffirming its reliability, validity, and factor structure, with the expectation of higher levels of worry compared to a non-SUD population at the beginning of treatment, which decline over time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10731911251327255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for a randomized controlled trial of patient-portal-based screening for substance use among people with HIV.
Front Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFSelf-Reported Personality Functioning in Patients With Substance Use Disorders: Similarities and Specifics With Respect to the Czech Community Sample.
Alpha Psychiatry
August 2025
Department of Addictology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
Objective: Information about the level of general personality functioning could provide benefits for tailoring substance use disorder (SUD) treatment. This study examined self-reported personality functioning among patients with SUD compared to the general population, gender specifics, and the psychometric properties of the Czech Level of Personality Functioning Scale-Self Report (LPFS-SR).
Methods: Two samples were used in this study.
Geographic and Policy Factors Influence Telehealth Availability for Substance Use Disorder Treatment.
J Behav Health Serv Res
September 2025
Department of Health Policy and Management, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, 4301 W. Markham St., Little Rock, AR, USA.
Telehealth is increasingly a standard and routine clinical option, indicating a changing outlook for SUD treatment from in-person to the more convenient option of telehealth. As populations across geographies increasingly prefer telehealth, more research is warranted that focuses on how where a person lives is associated with telehealth availability. The authors used the Mental Health and Addiction Treatment Tracking Repository (MATTR 2024) to identify telehealth availability among all known licensed SUD treatment facilities in the USA (N = 10,492 facilities).
View Article and Find Full Text PDFAn Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies.
Blood Adv
September 2025
AP-HP, Hôpital Saint Louis and University of Paris, INSERM U944 and THEMA insitute, Paris, France.
Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.
View Article and Find Full Text PDF